radRounds Radiology Network

Connecting Radiology | Enabling collaboration and professional development

Information

RadNet Management, Inc

Website: http://www.RadNet.com
Members: 4
Latest Activity: Sep 12, 2010

New 2010 CA Law:

AB 359 (Nava) - Requires digital mammography screening to be covered under the "Every Woman Counts" (EWC) Cancer Detection Program administered by the California Department of Public Health when analog mammography is not available.

Discussion Forum

Aspirin cuts death risk after breast cancer

WASHINGTON - Breast cancer survivors who take aspirin regularly may be less likely to die or have their cancer return, U.S. researchers reported Tuesday. The study of more than 4,000 nurses showed…Continue

Started by RadNet Management, Inc. Feb 17, 2010.

Radiotherapy For Breast Cancer - Dosage Questions

Radiotherapy For Breast Cancer - Dosage Questions…Continue

Started by RadNet Management, Inc. Feb 8, 2010.

NeuroQuant: Reducing MRI Analysis Time from 100 Hours to Less than 10 Minutes

Breakthrough: Unmasking Early-Stage Alzheimer's DiseaseReducing MRI Analysis Time from 100 Hours to Less than 10…Continue

Tags: alzheimers, neuroquant

Started by RadNet Management, Inc. Dec 28, 2009.

MRI volume navigation adds accuracy to second-look breast ultrasound

MRI volume navigation adds accuracy to second-look breast ultrasoundBy Brian CaseyAuntMinnie.com staff writerNovember 11, 2009Sunday, November 29 | 12:30 p.m.-1:30 p.m. | LL-BR4062-B07 | Lakeside…Continue

Tags: cancer, breast, Mammogram, ultrasound, MRI

Started by RadNet Management, Inc. Dec 28, 2009.

Comment Wall

Comment

You need to be a member of RadNet Management, Inc to add comments!

Comment by RadNet Management, Inc. on March 10, 2010 at 5:52pm
A Third Study Finds Bisphosphonates Reduce Breast Cancer Risk

Zosia Chustecka

March 10, 2010 — A third study, and the first to be published, has found a reduction in the risk for breast cancer among postmenopausal women taking bisphosphonates for the treatment of osteoporosis.

The new finding, reported in the March 2 issue of the British Journal of Cancer, comes from a case–control analysis of more than 6000 women in Wisconsin, half of whom were diagnosed with invasive breast cancer. It found that the use of bisphosphonates was associated with a 30% reduction in the risk for breast cancer.

"This large study provides new evidence that the use of bisphosphonates is associated with a potentially important reduction in breast cancer risk," lead author Polly Newcomb, PhD, MPH, head of the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center in Seattle, Washington, said in a statement.

This reduction in breast cancer risk is similar to that already reported in 2 other studies, both of which were presented in December 2009 at the San Antonio Breast Cancer Symposium. One was an analysis of more than 150,000 postmenopausal women participating in several Women's Health Initiative studies, which found that bisphosphonate use reduced the risk for invasive breast cancer by 32%. The other involved an analysis of 4575 postmenopausal women in Israel, which found a 34% reduction.

At the time, the fact that a similar finding came out of 2 geographically different populations was described as "encouraging," by Theresa Guise, MD, professor of medicine and oncology at the Indiana University School of Medicine in Indianapolis, who was not involved in either study. However, she cautioned that "this needs to be confirmed by controlled clinical trials."

There was some discussion at that meeting about possible confounding factors. For example, women who were taking bisphosphonates for osteoporosis would have low bone-mineral density, and this in itself would indicate lower estrogen levels, which would influence the risk for breast cancer.

Accounting for Confounding Factors

In the latest study, Dr. Newcomb and colleagues emphasized that they were able to account for important confounders, such as body mass index and postmenopausal hormone use.

In addition, they analyzed the reasons for which bisphosphonates were prescribed, such as fractures, height loss, and physician-diagnosed osteoporosis. There was a suggestion that the use of bisphosphonates was associated with a reduced risk for breast cancer only among women reporting symptoms of bone loss, but this was not statistically significant.

"This association was not attributed to the primary indication for use, bone density loss, or fractures, which we and others have previously shown as a risk factor for breast cancer," the authors write.

The researchers therefore conclude that "these findings may reflect real benefits due to antitumor mechanisms" of bisphosphonates.

However, the association with a reduction in the risk for breast cancer was seen only among women who were not obese; they were not seen among obese women. This suggests that the inhibitory action of these drugs is related to some threshold effect of hormonal or other growth factors, which are known to be important etiological exposures in breast cancer, the researchers write in their paper.

"Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk," Dr. Newcomb added in a statement.

How bisphosphonates could prevent breast cancer is not known, but these drugs have several actions that might be relevant; they have been shown to cause tumor apoptosis, inhibit angiogenesis, and prevent tumor-cell adhesions. "These drugs may affect cell function and be important in cell growth and death — specifically the death of tumors or even premalignant disease," Dr. Newcomb noted.

There has also been a large study reporting beneficial antitumor effects of bisphosphonates in women who already have breast cancer, which hints of this effect from another 2 studies. A recent editorial in the Journal of Clinical Oncology (2009;27:4043-4046) discussing these findings suggested that in the "seed and soil" hypothesis for cancer development, bisphosphonates might create an "unfavorable soil" in which the development of cancer cells is thwarted.


MedScape: http://www.medscape.com/viewarticle/718235?sssdmh=dm1.600238&sr...
Comment by RadNet Management, Inc. on February 17, 2010 at 4:16pm
Patient Service Coordinator needed in Pleasanton, CA Apply online @ http://www.radnet.com/careerDetail.php?recordID=4310
Comment by RadNet Management, Inc. on February 8, 2010 at 3:06pm
Radiotherapy For Breast Cancer - Dosage Questions
http://blogs.myspace.com/index.cfm?fuseaction=blog.ListAll&bID=...
Comment by RadNet Management, Inc. on February 4, 2010 at 6:08pm
Medical Scheduler needed in Newark, DE
Apply Online @ http://www.radnet.com/careerDetail.php?recordID=2055
Comment by RadNet Management, Inc. on February 2, 2010 at 5:18pm
RadNet Inc. to Present at the UBS 20th Annual Global Healthcare Services Conference on Tuesday, February 9th, 2010. Read more here: http://www.radnet.com/newsDETAIL.php?recordID=375
Comment by RadNet Management, Inc. on December 28, 2009 at 3:18pm
Mammography Technologist needed in Towson, MD
Apply Online @ http://www.radnet.com/careerDetail.php?recordID=2039
Comment by RadNet Management, Inc. on December 28, 2009 at 3:16pm
Multi Modality Technologist needed in Germantown, MD
APPLY ONLINE: http://www.radnet.com/careerDetail.php?recordID=2031
Comment by RadNet Management, Inc. on December 28, 2009 at 3:16pm
Marketing Representative needed in Palm Desert, CA
APPLY ONLINE: http://www.radnet.com/careerDetail.php?recordID=4295
Comment by RadNet Management, Inc. on December 28, 2009 at 3:16pm
Accounts Receivable Follow Up Coordinator needed in Topeka, KS
APPLY ONLINE: http://www.radnet.com/careerDetail.php?recordID=2033
Comment by RadNet Management, Inc. on December 28, 2009 at 3:16pm
Medical Administrative Assistant needed in West Los Angeles
APPLY ONLINE: http://www.radnet.com/careerDetail.php?recordID=4296
 

Members (3)

 
 
 

Sponsor Ad

© 2017   Created by radRounds Radiology Network.   Powered by

Badges  |  Report an Issue  |  Terms of Service